CELECOXIB

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-20-R-0075

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents5
The Defense Logistics Agency (DLA) Troop Support has issued a solicitation, identified by procurement number SPE2D2-20-R-0075, for the supply of Celecoxib, a pharmaceutical product. This notice serves as a modification to announce the exercise of the third option year under the existing contract, indicating the agency’s continued requirement for this medication and its intent to maintain an uninterrupted supply for its stakeholders. The scope of this procurement centers on the manufacturing and delivery of Celecoxib, classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505, which pertains to drugs and biologicals. The primary objective is to ensure the reliable provision of Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) commonly used for pain management and inflammation reduction, to meet the ongoing needs of federal entities supported by DLA Troop Support. Contractors responding to this opportunity should be capable of producing pharmaceutical-grade Celecoxib in compliance with all applicable federal standards and regulations. Key requirements include adherence to quality assurance protocols, timely delivery schedules, and the ability to support the contract throughout its lifecycle, including option years. The expected deliverables are consistent, high-quality supplies of Celecoxib, with documentation and packaging that meet DLA specifications. DLA Troop Support, a federal office, is the contracting entity overseeing this procurement. Interested parties may direct inquiries to the designated contacts: Ryan Guarnere ([email protected], 215-737-3182) and Jason Wray ([email protected], 215-737-0614). The solicitation remains active as of the posting date, May 6, 2025, with reference materials and attachments available via the official SAM.gov opportunity listing (Opportunity ID: ba1032b4a7a840d6bea38dce6b0bdce0). This procurement is a standard federal solicitation, and while no specific set-aside requirements or special considerations are noted in the provided information, contractors should review all attachments and referenced documents for further details. The contract’s fundamental elements—pharmaceutical manufacturing, quality assurance, and reliable supply—will remain constant throughout the contract’s duration, including any exercised option years. Contractors with proven capabilities in pharmaceutical preparation manufacturing, particularly those experienced in supplying federal agencies, are encouraged to evaluate this opportunity for alignment with their operational strengths and compliance capacities.